A urine-based test called NephroCheck can accurately predict the development of acute kidney injury through the presence of the FDA-approved biomarker called TIMP-2/IGFBP7. But so far its worldwide clinical impact has been limited. Now a group of medical researchers have pioneered the BRAVA study, to assess if NephroCheck can accurately predict acute kidney injury in patients with critical illness admitted to the emergency department.

DOI: [ Ссылка ]

#Acutekidneyinjury
#Mortality
#Emergencydepartment
#NephroCheck
#Patientswithcriticalillnesses
#대한진단검사의학회
#대한진단검사의학회지
#진검
#ALM
#AnnLabMed
#Annals_of_Laboratory_Medicine
#Korea_Society_for_Laboratory_Medicine

свернуть